
Raising Health
Andreessen Horowitz, a16z Bio + HealthAudio
- Format:
- Podcast
- New episodes:
- Irregular
- Typical length:
- about 40 minutes
- Latest episode:
About this show
A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vineeta Agarwala, Julie Yoo, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg Verdine, Fei-Fei Li, and Suchi Saria, as they explore the intricacies of these technological advancements and how they can be built and effectively delivered. Together, we can rewrite the script. Welcome to Raising Health.
Covers: health technology, artificial intelligence, healthcare, biotechnology, venture capital, health insurance, electronic health records, clinical AI, mrna vaccines, behavioral health
Show details and episodes come from the publisher's public feed at feeds.simplecast.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
Raising Health, from a16z Bio + Health, features experts discussing the challenges and opportunities of building new health and biotech companies. Recent episodes cover AI in health insurance and clinical settings, health data and interoperability, mRNA cancer vaccine results, and peptides and sleep technology.
Cosmos
Similar in subject
- Y Combinator
Both cover: biotechnology, venture capital, artificial intelligence - Knock Knock, Hi! with the Glaucomfleckens
Both cover: healthcare, health insurance, artificial intelligence - Becker’s Healthcare Podcast
Both cover: healthcare, health insurance, artificial intelligence
Similar shows
Explore more
Episodes
The AI-Native Health Plan | UnitedHealth Group’s Dan Kueter
· 38 min
Can AI finally make healthcare cheaper? UnitedHealth Group Chief Commercial Officer Dan Kueter believes it can, potentially within a single-digit number of years, but only once AI moves beyond automating existing administrative work and starts enabling things the healthcare system couldn’t do before. At a16z BUILD, Dan joins General Partner Julie Yoo to discuss a generational shift in employer-sponsored health insurance, why self-funded plans are becoming accessible to smaller employers, and how AI is changing everything from underwriting and distribution to consumer navigation. They also get into UnitedHealthcare’s goal of eliminating 30% of prior authorizations, what a “touchless” version could eventually look like, and why personal AI agents could become a new front door to healthcare, forcing insurers to meet consumers wherever they choose to interact. Resources: Follow Dan Kueter on Linkedin: https://www.linkedin.com/in/dankueter/ Follow Julie Yoo on X:https://x.com/julesyoo Learn more about a16z Bio + Health:https://a16z.com/bio-health/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetThe Next Era of Health Data: AI, Open APIs, and the End of the EHR Oligopoly
· 34 min
Healthcare spent the last 15 years digitizing medical records. Now the challenge is making that data useful to patients, AI agents, and new health technology companies. National Coordinator for Health IT Dr. Tom Keane says the next phase is about interoperability, patient access, and lowering barriers for new entrants. Tom joins a16z’s Julie Yoo and Colin Rom to discuss how healthcare data can move more easily through APIs and TEFCA, how wearables and AI-generated data fit in, and where privacy and security concerns can become competitive moats. And when Julie asks when AI might produce a serious new competitor to today’s dominant electronic health record companies, Tom predicts: within one to two years. Resources: Follow Thomas Keane on LinkedIn: https://www.linkedin.com/in/thomas-keane-b41a5012/ Follow Julie Yoo on X:https://x.com/julesyoo Follow Colin Rom on X: https://x.com/CF_Rom Office of the National Coordinator for Health IT:https://healthit.gov Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetBuilding the Store for Healthcare | General Medicine
· 42 min
AI is making healthcare advice abundant. But what happens when you actually need to act on it? General Medicine CEO TJ Parker argues that the new bottleneck is getting the lab, booking the specialist, filling the prescription, or understanding what any of it will cost. At BUILD 2026, a16z General Partner Vineeta Agarwala sits down with TJ to unpack General Medicine's vision for a healthcare “store”: one place where patients can understand their options, prices, and insurance coverage, then actually get care. They discuss why convenience can materially change patient behavior, how AI can connect medical records and benefits to the right next step, and what TJ learned building PillPack and Amazon Pharmacy about making a complicated healthcare system feel simple. Resources: Follow TJ Parker: https://x.com/tjparker Follow Vineeta Agarwala: https://x.com/vintweeta Learn more about General Medicine: https://generalmedicine.co/ Learn more about a16z Bio + Health:https://a16z.com/bio-health/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetModerna CEO Stéphane Bancel on the Next Era of mRNA
· 40 min
a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetClinical AI Comes of Age | Suchi Saria on the Future of Healthcare
· 46 min
Julie Yoo sits down with Dr. Suchi Saria, founder and CEO of Bayesian Health, to discuss the current state of clinical AI and what it takes to deploy AI systems in real-world healthcare settings. While much of the recent attention around AI has focused on copilots, chatbots, and administrative workflows, Saria argues that the greatest opportunity lies in helping clinicians make better decisions at the point of care. She explains how Bayesian Health's clinical intelligence platform continuously analyzes multimodal patient data to identify signs of deterioration, sepsis, and other high-risk conditions before they become medical emergencies. The conversation explores FDA approval, reimbursement, clinician trust, AI governance, hospital workflows, and why healthcare requires a higher standard of evidence than most software categories. Along the way, Saria shares lessons from bringing AI into clinical practice, the future of proactive medicine, and why the next era of healthcare may be defined by continuous intelligence rather than reactive care. Resources: Follow Suchi Saria on X:https://x.com/suchisaria Follow Julie Yoo on X:https://x.com/julieyoo Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetAI, Healthcare, and 700 Million Patients | Nicolas Abad, Telepatía
· 26 min
Nicolás Abad, founder and CEO of Telepatía, joins a16z to discuss building AI-powered tools for healthcare in Latin America. Inspired by the loss of his father to a preventable medical error, Adbad set out to address one of the region’s most significant challenges: a shortage of doctors, fragmented medical records, and limited healthcare infrastructure across a population of more than 700 million people. Telepatía's first product acts as a clinical copilot, helping physicians document visits, access patient context, and make more informed decisions. The conversation explores healthcare delivery in Latin America, AI-assisted medicine, medical errors, electronic health records, and why Abad believes AI can help expand access to care while improving outcomes. Along the way, he shares his vision for building an “AI doctor for doctors” and the long-term goal of transforming healthcare across the region. Resources: Follow Nicolás on X: https://x.com/Nicobot01 Follow Gabriel on X: https://x.com/GEVS94 Follow Daisy on X:https://x.com/daisywolfhttps://x.com/daisydwolf Follow Eva on X: https://x.com/evajsteinman Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetHealthcare Will Benefit Most from AI | Julie Yoo on StartUp Health
· 28 min
This episode originally aired on StartUp Health. Unity Stoakes speaks with Julie Yoo, general partner at a16z, about why healthcare is poised to benefit more from AI than any other industry, how the business profile of health tech companies has fundamentally shifted, and what founders need to show up with today to stand out at the seed and Series A stages. Resources: Follow Julie Yoo on X: https://x.com/julesyoo Follow Unity on X: https://x.com/unitystoakes Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetAndrew Huberman: Peptides, Sleep Tech, and the End of Obesity
· 51 min
Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years. Resources: Follow Andrew Huberman on X: https://twitter.com/hubermanlab (https://x.com/hubermanlab) Follow Daisy Wolf on X: https://twitter.com/daisydwolf (https://x.com/daisydwolf) Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetRebuilding Behavioral Health’s Operating System with AI
· 36 min
a16z Partners Daisy Wolf and Eva Steinman talk with Zach Cohen and Raymond Wang, cofounders of Ease Health, a company building an AI operating system for behavioral health that combines CRM, EHR, and revenue cycle management into a single platform. They discuss why behavioral health software has lagged behind, what it means to build AI native versus AI integrated, and why Zach left his job as an investor at a16z to go build in this space. They also cover how Ease plans to replace the dozen software vendors most practices rely on today. Resources: Follow Daisy Wolf on X: https://x.com/daisydwolf Follow Eva Steinman on LinkedIn: https://www.linkedin.com/in/eva-steinman/ Follow Zach Cohen on X: https://x.com/zachcohen25 (https://x.com/zachcohen25?lang=en) Follow Raymond Wang on LinkedIn: https://www.linkedin.com/in/arrays/ Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X:https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetAI in Healthcare: The Leapfrog Opportunity
· 25 min
At the Oliver Wyman Health Innovation Summit 2025, Julie Yoo, General Partner at a16z Bio + Health, makes the case that healthcare is uniquely positioned to benefit from AI more than any other industry. She argues that healthcare's historical underinvestment in technology is now an asset, enabling the industry to leapfrog directly to AI-native models of care delivery with unprecedented speed and scale. Resources: Follow Julie Yoo on X: https://x.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetAmbience CEO Nikhil Buduma on AI in Clinical Workflows
· 49 min
a16z general partner Julie Yoo talks with Nikhil Buduma, CEO and cofounder of Ambience Healthcare, to discuss how AI is transforming clinical workflows. They cover the early days of deep learning, why Ambience started by running a medical practice before building a platform company, and what it takes to achieve high clinician adoption rates at major academic medical centers. They also dig into the challenge of building products when AI capabilities change every few months, the real ROI that's finally converting CFOs, and why this might be the moment to reimagine the legacy EHR stack. Resources: Follow Nikhil Buduma on X: https://twitter.com/nkbuduma (https://x.com/nkbuduma) Follow Julie Yoo on X: https://twitter.com/julesyoo (https://x.com/julesyoo) Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetBuilding the Marketplace for AI’s Most Valuable Asset
· 38 min
a16z investors Daisy Wolf and Eva Steinman talk with Bobby Samuels, cofounder and CEO of Protege. They discuss the myth that we've run out of data for AI, how Protege connects healthcare systems and other data holders with the major AI labs, and why real-world data beats synthetic data for training models. Bobby also covers the growing demand for eval datasets, expanding beyond healthcare into video and audio, and what he's seeing from the biggest AI companies as they race to acquire training data. Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetMaking Healthcare Affordable for 80 Million Americans
· 37 min
Recently, a16z Bio + Health general partner Julie Yoo spoke with Nikita Singareddy, cofounder of Fortuna, and Florian Otto, cofounder of Cedar. They talked about why healthcare affordability is reaching a breaking point, how AI voice agents are transforming patient financial experiences, and what it will take to leapfrog decades of administrative burden in Medicaid—from 30-page paper applications to legacy technology systems built in the 1990s to the real opportunity for giving every American a "five-star healthcare experience." Resources: Follow Julie Yoo on X: https://twitter.com/julesyoo Follow Nikita Singareddy on X: https://twitter.com/singareddynm (https://x.com/singareddynm) Check out Fortuna: https://www.fortunahealth.com/ Follow Florian Otto on X: https://twitter.com/flottobrasil (https://x.com/flottobrasil) Check out Cedar: https://www.cedar.com/ Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetHealthcare 2026: AI Doctors, GLP-1s, and Insurance Defection
· 1 hr 34 min
Out-of-Pocket is a healthcare education company founded by Nikhil Krishnan that helps people understand how healthcare works and how to navigate it in practice. In this episode, a16z investing partner Jay Rughani and Nikhil discuss why health insurance is losing its role as the default way people access care. They explain how rising costs are pushing more consumers to pay out of pocket for diagnostics, preventive care, and navigation. The conversation also looks at what this shift means for startups, AI-powered tools, regulation, and access as healthcare continues to move beyond insurance. Resources: Follow Jay Rughani on X: https://twitter.com/JayRughani (https://x.com/JayRughani) Follow Nikhil Krishnan on X: https://twitter.com/nikillinit Read Out of Pocket’s 2026 Predictions: https://www.outofpocket.health/p/out-of-pockets-2026-predictions Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details, please see http://a16z.com/disclosures Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetBuilding AI Foundation Models for Molecular Design
· 47 min
Cofounders Jeremy Wohlwend and Gabriele Corso join the a16z podcast to discuss the launch of Boltz, a public benefit company building AI infrastructure for molecular biology. The conversation explains how breakthroughs following AlphaFold moved the field beyond protein structure prediction into modeling biomolecular interactions and binding strength, why open-source Boltz models saw rapid adoption across pharma and biotech, and how that work is now being productized. They outline the launch of Boltz Lab, a platform that brings protein and small-molecule design agents into scientist workflows, Boltz’s decision to operate as an infrastructure company rather than a therapeutics company, and how AI could reduce early drug discovery bottlenecks by improving molecular design and speeding iteration between computation and the lab. Resources: Follow Gabriele on X: https://twitter.com/GabriCorso Follow Jeremy on X: https://twitter.com/jeremyWohlwend Follow Jorge X: https://twitter.com/jorgecondebio Follow Zak on X: https://twitter.com/zakdoric Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X:https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://twitter.com/eriktorenberg](https://x.com/eriktorenberg (https://x.com/eriktorenberg](https://x.com/eriktorenberg) Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetHow AI Cut Healthcare Burnout by 70%
· 47 min
In this episode, a16z GP Julie Yoo sits down with Peter McCanna, CEO of Baylor Scott & White Health, to break down how one of America's largest health systems is transforming from a supply-driven "walled castle" to a customer-centric ecosystem, and how it's achieving a 10% operating margin while most hospitals struggle to stay in the black. They get into why helping his father navigate healthcare convinced Pete the entire system is fundamentally broken, what differentiates academic medical centers from community health systems, and why traditional hospital economics root out essential services like behavioral health. Peter also explains how ambient AI reduced physician burnout rates by 70%, why AI will eventually replace any job involving human-screen interaction, and what he looks for in startup partnerships beyond just TAM and business fundamentals. Resources: Follow Peter on LinkedIn: https://www.linkedin.com/in/peter-mccanna-784619104 Follow Julie on X: @julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX (https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX?si=70ca2d87cf9342d9) Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetThe Future of Healthcare Payments: CMS Chief of Staff Stephanie Carlton
· 26 min
A labor and delivery nurse who ran Senate healthcare policy now manages $1.7 trillion in federal health spending—and she runs her team like a startup. Steph Carlton, Chief of Staff and Deputy Administrator at CMS, reveals the OKRs driving Medicare and Medicaid, why they're killing social determinants funding while building consumer health apps at scale, and how real-time provider data could collapse the 18-month lag between care delivery and payment. The team mixing founders with policy veterans is rewriting quality measures around VO2 max and app engagement, not just disease management—because preventing illness years before it happens might finally be worth more than treating it after. Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetHow to Build This Generation's Big Pharma Company
· 41 min
Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio’s hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today’s market.\ Timecodes: 0:00 Introduction 0:38 Why Formation Bio? Origins and Mission 1:12 The Real Bottleneck: Clinical Development 4:56 Formation Bio’s Business Model 7:50 Picking Winners: The Art and Science of Drug Selection 11:54 First-in-Class vs. Best-in-Class Strategies 14:04 Overcoming Regulatory and Market Challenges 17:26 The Stakes: Can We Approve More Drugs? 19:07 How Formation Bio Cuts Cost and Time 21:43 AI’s Role in Drug Development 25:10 The Future: From 50 to 500 Drug Approvals? 35:18 Global Competition: The Rise of China 39:28 The Path Forward: Data, Regulation, and Access 41:47 Conclusion: Realizing the AI Revolution in Pharma Resources: Find Ben on X: https://x.com/BenjamineYLiu Find Jorge on X: https://x.com/JorgeCondeBio Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the Raising Health Podcast on Spotify: https://open.spotify.com/show/4fjb8YTzHDuPBgDXc3ElkR Listen to the Raising Health Podcast Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/raising-health/id1529318900 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetCVS Health: Building Healthcare’s Consumer Platform
· 27 min
Josh Weiner left Meta to return to CVS Health with two painful realizations: consumers don't manage their health—they expect it, and the healthcare market fundamentally violates every principle of economics. In this conversation with a16z's Julie Yoo, the CVS Senior VP explains why 50% of Americans can't afford a healthcare emergency, how CVS is becoming a platform to solve structural healthcare problems, and why the future depends on consumers finally controlling their own health data. Timecodes: 0:00 The Healthcare Market Isn't Functioning 2:30 Consumers Don't Manage Health, They Just Expect It 3:39 Why Consumer Playbooks Die in Healthcare 5:41 Motion vs Progress: The Innovation Illusion 8:46 Platform Philosophy: "It Takes a Village" 11:38 The Vaccine Paradox Under One Roof 19:37 The 40% Hidden Reality: Healthcare Is Caregiving 21:04 The Deductible Comprehension Crisis 22:10 "This Does Have an Expiration Date" 24:40 The Health Passport Future Resources: Find Josh on LinkedIn: https://www.linkedin.com/in/joshweiner2/ Follow Julie on X: https://x.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the Raising Health Podcast on Spotify: https://open.spotify.com/show/4fjb8YTzHDuPBgDXc3ElkR Listen to the Raising Health Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/raising-health/id1529318900 Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetDyno Therapeutics: Empowering Patients with Genetic Agency
· 47 min
For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells. Eric Kelsic, CEO of Dyno Therapeutics, joins a16z's Jorge Conde to explain how AI-designed protein shells are solving gene therapy's delivery crisis. They explore why Huntington's patients can now get 15 extra years of healthy life, how Dyno inverted the liver-to-brain delivery ratio by 1000x, and why capsids evolved by nature are now being designed by machine learning models trained on millions of variants. Eric introduces the concept of genetic agency—humanity's first-ever ability to take action at the DNA level—and details why solving delivery for common diseases will make ultra-rare disease treatments economically viable. Plus: what happens when gene therapy requires neurosurgery today but could be a simple injection tomorrow, why recent deaths in clinical trials prove we need better technology now, and how genetic medicine could become as routine as surgery within our lifetimes. Resources: Follow Eric on X: https://x.com/ekelsic Follow Jorge on X: https://x.com/JorgeCondeBio Learn more about GATC 2025: https://www.dynotx.com/gatc2025 Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yet